CNS Pharmaceuticals, Inc. (NASDAQ:CNSP – Get Free Report) saw a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 364,600 shares, a growth of 80.0% from the August 31st total of 202,500 shares. Based on an average daily volume of 5,550,000 shares, the days-to-cover ratio is currently 0.1 days.
CNS Pharmaceuticals Stock Performance
Shares of NASDAQ:CNSP remained flat at $0.14 during mid-day trading on Friday. 670,562 shares of the company were exchanged, compared to its average volume of 2,014,493. The company has a market cap of $203,318.70, a price-to-earnings ratio of 0.00 and a beta of 2.58. The stock has a fifty day moving average of $0.28 and a 200 day moving average of $6.04. CNS Pharmaceuticals has a 1-year low of $0.10 and a 1-year high of $137.50.
CNS Pharmaceuticals (NASDAQ:CNSP – Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($6.72) EPS for the quarter.
Institutional Trading of CNS Pharmaceuticals
Analyst Ratings Changes
Separately, Maxim Group upgraded shares of CNS Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a research report on Tuesday, September 10th.
Read Our Latest Stock Analysis on CNSP
About CNS Pharmaceuticals
CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.
See Also
- Five stocks we like better than CNS Pharmaceuticals
- How to Invest in Insurance Companies: A Guide
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- MarketBeat Week in Review – 9/23 – 9/27
- What Are Dividend Champions? How to Invest in the Champions
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.